I still see solid earnings growth for the sector. Growth looks strong especially when you consider (expected sector) growth of 13-to-14 percent, compared to an (expected) S&P 500 drop of about 7-to-8 percent. |
It's tougher this year for the prescription allergy drugs. |
Schering-Plough is hanging in there. |